The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | UCARTCS1: a novel allogeneic CAR-T therapy for myeloma
Roman Galetto, PhD, Cellectis, Paris, France, briefly discusses UCARTCS1, a novel allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developed for the treatment of multiple myeloma. Dr Galetto also highlights the challenges associated with developing CAR-T products that target CS1, and the benefits of using this novel approach for the treatment of myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Cellectis employee
